The 18th Meeting of the International Society of Amyloidosis was held in Heidelberg, Germany, from September 4-8. This meeting brought together experts as they discussed novel therapies, clinical trial updates, and the diagnosis and management of amyloidosis.
View all videos

ISA 2022

The 18th Meeting of the International Society of Amyloidosis
04–08 September 2022 | Heidelberg, Germany / Online
VJHemOncVJHemOnc@VJHemOnc·
3h

We spoke to @adamssperling (@DanaFarber), who shared some insights into the role of clonal hematopoiesis in multiple myeloma and other hematological malignancies:

🎥: http://ow.ly/GGiK50KVRjM

#MMsm #HemOnc #BloodCancerAwarenessMonth #IMS2022

Reply on Twitter 1575727491070808071Retweet on Twitter 15757274910708080711Like on Twitter 15757274910708080714View Tweet 1575727491070808071
VJHemOncVJHemOnc@VJHemOnc·
12h

We had a great interview with Catherine Coombs of @UNC, who shared some insights into novel BTK inhibitors in CLL and future outlooks.

@SocietyofHemOnc #SOHO22 #HemOnc #LeuSM #CLLsm

Reply on Twitter 1575595071273021442Retweet on Twitter 15755950712730214421Like on Twitter 15755950712730214423View Tweet 1575595071273021442
VJHemOncVJHemOnc@VJHemOnc·
12h

#SOHO22 | Peter Valk (@ErasmusMC) discusses TP53-mutated AML and MDS, the prognostic value of FLT3-ITD residual disease in AML, and more.

Visit http://VJHemOnc.com for our interviews from this year's meeting!

#SOHO2022 #HemOnc #LeuSM #AMLsm #MDSsm

Reply on Twitter 1575591500834295808Retweet on Twitter 15755915008342958081Like on Twitter 15755915008342958082View Tweet 1575591500834295808
Retweet on TwitterVJHemOnc Retweeted
MDAndersonNewsMD Anderson Cancer Center@MDAndersonNews·
12h

At #SOHO22: Our Dr. Robert Orlowski discusses early data in bispecific T cell engagement for treatment of multiple myeloma. @Myeloma_Doc #EndCancer

Reply on Twitter 1575586597206007809Retweet on Twitter 15755865972060078091Like on Twitter 15755865972060078096View Tweet 1575586597206007809
Load More...

ISA 2022

The 18th Meeting of the International Society of Amyloidosis
04–08 September 2022 | Heidelberg, Germany / Online
The 18th Meeting of the International Society of Amyloidosis was held in Heidelberg, Germany, from September 4-8. This meeting brought together experts as they discussed novel therapies, clinical trial updates, and the diagnosis and management of amyloidosis.
View all videos
VJHemOncVJHemOnc@VJHemOnc·
3h

We spoke to @adamssperling (@DanaFarber), who shared some insights into the role of clonal hematopoiesis in multiple myeloma and other hematological malignancies:

🎥: http://ow.ly/GGiK50KVRjM

#MMsm #HemOnc #BloodCancerAwarenessMonth #IMS2022

Reply on Twitter 1575727491070808071Retweet on Twitter 15757274910708080711Like on Twitter 15757274910708080714View Tweet 1575727491070808071
VJHemOncVJHemOnc@VJHemOnc·
12h

We had a great interview with Catherine Coombs of @UNC, who shared some insights into novel BTK inhibitors in CLL and future outlooks.

@SocietyofHemOnc #SOHO22 #HemOnc #LeuSM #CLLsm

Reply on Twitter 1575595071273021442Retweet on Twitter 15755950712730214421Like on Twitter 15755950712730214423View Tweet 1575595071273021442
VJHemOncVJHemOnc@VJHemOnc·
12h

#SOHO22 | Peter Valk (@ErasmusMC) discusses TP53-mutated AML and MDS, the prognostic value of FLT3-ITD residual disease in AML, and more.

Visit http://VJHemOnc.com for our interviews from this year's meeting!

#SOHO2022 #HemOnc #LeuSM #AMLsm #MDSsm

Reply on Twitter 1575591500834295808Retweet on Twitter 15755915008342958081Like on Twitter 15755915008342958082View Tweet 1575591500834295808
Retweet on TwitterVJHemOnc Retweeted
MDAndersonNewsMD Anderson Cancer Center@MDAndersonNews·
12h

At #SOHO22: Our Dr. Robert Orlowski discusses early data in bispecific T cell engagement for treatment of multiple myeloma. @Myeloma_Doc #EndCancer

Reply on Twitter 1575586597206007809Retweet on Twitter 15755865972060078091Like on Twitter 15755865972060078096View Tweet 1575586597206007809
Load More...

Latest Videos

View all
0:57
Phenotypic variability & getting to the right diagnosis in AL amyloidosis
Marianna Fontana • 14 Sep 2022
2:41
Optimizing the use of daratumumab in AL amyloidosis
Camille Vanessa Edwards • 7 Sep 2022
3:51
Current diagnostic and management strategies for ATTR amyloidosis
Ramzi Tabbalat • 6 Sep 2022
2:58
The potential role of PET/CT imaging in the early diagnosis and monitoring of ATTR amyloidosis
Jonathan Wall • 14 Sep 2022

AL Amyloidosis

View all
0:57
Phenotypic variability & getting to the right diagnosis in AL amyloidosis
Marianna Fontana • 14 Sep 2022
2:41
Optimizing the use of daratumumab in AL amyloidosis
Camille Vanessa Edwards • 7 Sep 2022
3:16
The potential of AT-02 as a therapeutic strategy in ATTR & AL amyloidosis
Jonathan Wall • 14 Sep 2022
3:59
Using an iPSC-derived model to understand the mechanisms driving light chain-induced cardiotoxicity
Camille Vanessa Edwards • 7 Sep 2022

ATTR Amyloidosis

View all
3:51
Current diagnostic and management strategies for ATTR amyloidosis
Ramzi Tabbalat • 6 Sep 2022
2:58
The potential role of PET/CT imaging in the early diagnosis and monitoring of ATTR amyloidosis
Jonathan Wall • 14 Sep 2022
3:16
The potential of AT-02 as a therapeutic strategy in ATTR & AL amyloidosis
Jonathan Wall • 14 Sep 2022
2:14
Imaging modalities to diagnose and monitor AL & ATTR amyloidosis
Marianna Fontana • 14 Sep 2022

Diagnosis

View all
0:57
Phenotypic variability & getting to the right diagnosis in AL amyloidosis
Marianna Fontana • 14 Sep 2022
3:51
Current diagnostic and management strategies for ATTR amyloidosis
Ramzi Tabbalat • 6 Sep 2022

Treatment

View all
2:41
Optimizing the use of daratumumab in AL amyloidosis
Camille Vanessa Edwards • 7 Sep 2022
3:51
Current diagnostic and management strategies for ATTR amyloidosis
Ramzi Tabbalat • 6 Sep 2022

Transplantation

View all
1:29
The impact of clonal features on the survival of patients with non-cardiac AL amyloidosis
Paolo Milani • 7 Sep 2022
1:43
Feasibility of double autologous stem cell transplantation in patients with AL amyloidosis
Eli Muchtar • 6 Sep 2022

Immuno-Oncology

View all
2:41
Optimizing the use of daratumumab in AL amyloidosis
Camille Vanessa Edwards • 7 Sep 2022
3:16
The potential of AT-02 as a therapeutic strategy in ATTR & AL amyloidosis
Jonathan Wall • 14 Sep 2022
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals